登录新浪财经APP 搜索【信披】查看更多考评等级 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 财说丨双轮驱动难掩业绩震荡，吉宏股份实控人开启减持潮 智通财经记者 | 陶知闲 吉宏股份 2025 年前三季度的业绩数据堪称 "亮眼"：营业收入 50.39 亿元，同比增长 29%；归属净利润 2.16 亿元，同比大幅增长 60%。 公司表示，增长核心来自两大主业的协同发力。其中，跨境社交电商业务是主要增长引擎，该业务营收 与利润均实现较大幅度增长，直接带动整体业绩提升。 包装业务则贡献了稳定支撑。公开信息显示，吉宏股份的纸制快消品包装业务在国内纸制包装市场占有 率位居首位，形成了较强的规模优势。 "跨境电商行业在 2025 年迎来阶段性复苏，叠加吉宏股份的泛品策略能够覆盖更多需求场景，这是其业 绩增长的重要外部因素。" 长期跟踪消费与跨境电商行业的分析师王玥伦对智通财经记者表示，"而包 装业务作为传统主业，依托头部客户的稳定订单，实现了稳健增长，两者形成了一定的互补效应。" 但光鲜数据背后，是公司近四年业绩的剧烈震荡，暴露出盈利能力的不稳定性。智通财经记者梳理数据 发现，2021 年至 ...

Core Viewpoint - Zhejiang Haiseng Medical Equipment Co., Ltd. is set to go public on the Beijing Stock Exchange, with an IPO of up to 11.2941 million shares, primarily relying on a distribution model for revenue generation, which poses inherent risks due to high dealer turnover and profitability discrepancies between new and exiting dealers [2][3][4]. Revenue and Profitability - The company reported revenues of 268 million yuan, 306 million yuan, 304 million yuan, and 156 million yuan for the years 2022 to 2024 and the first half of 2025, with net profits of 70.11 million yuan, 78.04 million yuan, 70.92 million yuan, and 35.39 million yuan, indicating a revenue decline of 0.7% and a net profit decline of 9.12% in 2024 [3][4]. - The main revenue source is anesthesia equipment, which accounted for 47.92% to 52.6% of total revenue during the reporting period, with sales increasing from 130 million yuan to 160 million yuan [3][4]. Distribution Model - The distribution model is the core sales channel, contributing 90.43%, 89.57%, 85.06%, and 83.16% of total revenue from 2022 to the first half of 2025, with over 80% of revenue generated through distributors [4][5]. - The dealer structure shows significant volatility, with over 200 dealers entering and exiting annually, leading to concerns about the stability and profitability of the distribution network [5][6]. Dealer Profitability - There is a notable difference in gross profit margins between new and exiting dealers, with exiting dealers consistently showing higher margins, indicating that the company earns more profit from exiting dealers compared to new ones [7][8]. Sales and Expenses - Sales expenses over the past three and a half years totaled approximately 105 million yuan, nearly double the R&D expenses of about 56.42 million yuan, with a sales expense ratio rising to 10.63%, significantly higher than the industry average of 6.25% [9][10]. - Employee compensation constitutes over 60% of sales expenses, with the company having a higher proportion of sales personnel compared to peers, yet generating lower revenue per employee [9][10][11]. Comparison with Peers - Compared to peers like Weili Medical and Sanxin Medical, Haiseng Medical has a higher proportion of sales personnel and higher average salaries, but lower revenue generation per employee, highlighting inefficiencies in personnel utilization [10][12].